Elliot Stieglitz

Elliot Stieglitz is an Assistant Professor in the Department of Pediatrics at the University of California San Francisco (UCSF) School of Medicine, specializing in pediatric hematology-oncology with a focus on juvenile myelomonocytic leukemia (JMML). His research integrates genomic profiling, targeted therapies, and clinical trial design to improve outcomes for children with high-risk leukemias.

Education:

• B.A. in Biology, Yeshiva University (2003)
• M.D., Stony Brook School of Medicine (2008)
• Residency in Pediatrics, NYPH-Weill Cornell Medical Center (2011)
• Fellowship in Pediatric Hematology-Oncology, UCSF (2014)

Dr. Stieglitz's research centers on JMML pathogenesis and treatment optimization. His team demonstrated that multi-hit mutations predict poor outcomes, DNA methylation profiling stratifies risk, and MEK inhibitors like trametinib show efficacy in relapsed disease. Current work focuses on risk-adapted front-line therapy combining trametinib and azacitidine (NCT05849662), funded by an NIH R37 grant. His publication analysis reveals concentrated expertise in RAS pathway targeting, immunotherapy development (particularly CAR-T cells), and genomic drivers of pediatric myeloid malignancies.

Key Scientific Awards:

• NIH K08 Award (National Heart Lung Blood Institute)
• Alex's Lemonade Stand Young Investigator Award
• St. Baldrick's Foundation Fellowship
• ASH/EHA Translational Training Program
• SIOP Young Investigator Award

As Principal Investigator on NIH R37CA266550 and former K08HL135434 awardee, he leads the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) consortium trial for newly diagnosed JMML. His laboratory investigates mutation-specific therapeutic vulnerabilities and collaborates with industry partners on novel agent development.